Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell-Derived NK Cell Therapies

Abstract

Advancements in the generation of human pluripotent stem cell-derived natural killer (PSC-NK) cells have attracted considerable attention within the biomedical research community, offering a promising off-the-shelf technique for universal immune therapy. However, this technique is associated with certain ethical, safety, and regulatory challenges, including ensuring genomic stability, preventing contamination and adhering to rigorous ethical standards for cell sourcing and obtaining informed consent. Addressing these challenges would require robust quality control, transparent data-sharing practices, and cross-border collaboration to ensure alignment with ethical and scientific standards. Future development must therefore focus on patient safety, data privacy and equitable access within a comprehensive ethical framework. These measures are crucial for maintaining public trust in and enabling the responsible clinical integration of PSC-NK therapies, thereby supporting their advancement while maintaining a balance between innovation and societal and ethical considerations.

Keywords

ethics / governance / natural killer cells / pluripotent stem cells / regulation

References

[1] K. V. Woan, H. Kim, R. Bjordahl, et al., “Harnessing Features of Adaptive NK Cells to Generate iPSC-Derived NK Cells for Enhanced Immunotherapy,” Cell Stem Cell 28 (2021): 2062–2075.e2065.

[2] F. Cichocki, R. Bjordahl, J. P. Goodridge, et al., “Quadruple Gene-Engineered Natural Killer Cells Enable Multi-Antigen Targeting for Durable Antitumor Activity Against Multiple Myeloma,” Nature Communications 13 (2022): 7341, https://doi.org/10.1038/s41467-022-35127-2.

[3] S. J. Lu and Q. Feng, “CAR-NK Cells From Engineered Pluripotent Stem Cells: Off-The-Shelf Therapeutics for All Patients,” Stem Cells Translational Medicine 10 (2021): S10–S17, https://doi.org/10.1002/sctm.21-0135.

[4] D. Huang, J. Li, F. Hu, et al., “Lateral Plate Mesoderm Cell-Based Organoid System for NK Cell Regeneration From Human Pluripotent Stem Cells,” Cell Discovery 8 (2022): 121, https://doi.org/10.1038/s41421-022-00467-2.

[5] A. Nianias and M. Themeli, “Induced Pluripotent Stem Cell (iPSC)–derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges,” Current Hematologic Malignancy Reports 14 (2019): 261–268.

[6] H. Khodayari, S. Khodayari, E. Ebrahimi, et al., “Stem Cells-Derived Natural Killer Cells for Cancer Immunotherapy: Current Protocols, Feasibility, and Benefits of Ex Vivo Generated Natural Killer Cells in Treatment of Advanced Solid Tumors,” Cancer Immunology, Immunotherapy 70 (2021): 3369–3395, https://doi.org/10.1007/s00262-021-02975-8.

[7] L. S. Assen, K. R. Jongsma, R. Isasi, M. A. Tryfonidou, and A. L. Bredenoord, “Recognizing the Ethical Implications of Stem Cell Research: A Call for Broadening the Scope,” Stem Cell Reports 16 (2021): 1656–1661, https://doi.org/10.1016/j.stemcr.2021.05.021.

[8] B. Lo and L. Parham, “Ethical Issues in Stem Cell Research,” Endocrine Reviews 30 (2009): 204–213, https://doi.org/10.1210/er.2008-0031.

[9] P. Morcillo-Martín-Romo, J. Valverde-Pozo, M. Ortiz-Bueno, et al., “The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances,” Biomedicine 13 (2025): 857, https://doi.org/10.3390/biomedicines13040857.

[10] G. Lian, T. S. Mak, X. Yu, and H. Y. Lan, “Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors,” International Journal of Molecular Sciences 23 (2021): 164, https://doi.org/10.3390/ijms23010164.

[11] Y. Yan, L. Jiang, Z. Zhu, et al., “A Scalable, Off-The-Shelf, and Cost-Effective NK Cell Manufacturing Platform for Developing NK Cell-Based Immunotherapy,” Blood 142 (2023): 6800–6800, https://doi.org/10.1182/blood-2023-181460.

[12] Y. L. Zheng, “Some Ethical Concerns About Human Induced Pluripotent Stem Cells,” Science and Engineering Ethics 22 (2016): 1277–1284, https://doi.org/10.1007/s11948-015-9693-6.

[13] M. C. Parikh, “Gene Editing: Developments, Ethical Considerations, and Future Directions,” Journal of Community Hospital Internal Medicine Perspectives 15 (2025): 1–4, https://doi.org/10.55729/2000-9666.1445.

[14] D. Kong, C. Du, and H. Wang, “Editorial: New Insights Into and Interventions of the Persistent Immune Responses in Chronic Graft Rejection,” Frontiers in Immunology 12 (2021): 759189, https://doi.org/10.3389/fimmu.2021.759189.

[15] E. W. Clayton, B. J. Evans, J. W. Hazel, and M. A. Rothstein, “The Law of Genetic Privacy: Applications, Implications, and Limitations,” Journal of Law and the Biosciences 6 (2019): 1–36, https://doi.org/10.1093/jlb/lsz007.

[16] K. Choucair, J. R. Duff, C. S. Cassidy, et al., “Natural Killer Cells: A Review of Biology, Therapeutic Potential and Challenges in Treatment of Solid Tumors,” Future Oncology 15 (2019): 3053–3069, https://doi.org/10.2217/fon-2019-0116.

[17] K. Rezvani, R. Rouce, E. Liu, and E. Shpall, “Engineering Natural Killer Cells for Cancer Immunotherapy,” Molecular Therapy 25, no. 8 (2017): 1769–1781.

[18] N. Lapteva, S. M. Szmania, F. van Rhee, and C. M. Rooney, “Clinical Grade Purification and Expansion of Natural Killer Cells,” Critical Reviews in Oncogenesis 19 (2014): 121–132, https://doi.org/10.1615/critrevoncog.2014010931.

[19] H. Matsubara, A. Niwa, T. Nakahata, and M. K. Saito, “Induction of Human Pluripotent Stem Cell-Derived Natural Killer Cells for Immunotherapy Under Chemically Defined Conditions,” Biochemical and Biophysical Research Communications 515 (2019): 1–8, https://doi.org/10.1016/j.bbrc.2019.03.085.

[20] H. Maysubara, A. Niwa, T. Nakahata, and M. K. Saito, “NK Cells From Human Pluripotent Stem Cells for Immunotherapy,” Blood 132 (2018): 4955, https://doi.org/10.1182/blood-2018-99-115499.

[21] B. H. Goldenson, P. Hor, and D. S. Kaufman, “iPSC-Derived Natural Killer Cell Therapies—Expansion and Targeting,” Frontiers in Immunology 13 (2022): 841107, https://doi.org/10.3389/fimmu.2022.841107.

[22] D. Huang, J. Li, F. Hu, et al., “Lateral Plate Mesoderm Cell-Based Organoid System for NK Cell Regeneration from Human Pluripotent Stem Cells,” Cell Discovery 8 (2022): 121, https://doi.org/10.1038/s41421-022-00467-2.

[23] P. S. Woll, B. Grzywacz, X. Tian, et al., “Human Embryonic Stem Cells Differentiate Into a Homogeneous Population of Natural Killer Cells With Potent In Vivo Antitumor Activity,” Blood 113 (2009): 6094–6101.

[24] H. Zhu, R. H. Blum, R. Bjordahl, et al., “Pluripotent Stem Cell–Derived NK Cells With High-Affinity Noncleavable CD16a Mediate Improved Antitumor Activity,” Blood 135 (2020): 399–410.

[25] L. J. Hsu, C. L. Liu, M. L. Kuo, C. N. Shen, and C. R. Shen, “An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells,” Biomedicine 9 (2021): 1323, https://doi.org/10.3390/biomedicines9101323.

[26] M. Tarannum, X. Ding, M. Barisa, et al., “Engineering Innate Immune Cells for Cancer Immunotherapy,” Nature Biotechnology 43 (2025): 516–533, https://doi.org/10.1038/s41587-025-02629-5.

[27] Y. R. Li, Z. S. Dunn, Y. Zhou, D. Lee, and L. Yang, “Development of Stem Cell-Derived Immune Cells for Off-The-Shelf Cancer Immunotherapies,” Cells 10 (2021): 3497, https://doi.org/10.3390/cells10123497.

[28] Y. Qin, Q. Cui, G. Sun, et al., “Developing Enhanced Immunotherapy Using NKG2A Knockout Human Pluripotent Stem Cell-Derived NK Cells,” Cell Reports 43 (2024): 114867, https://doi.org/10.1016/j.celrep.2024.114867.

[29] I. Dean, C. Y. C. Lee, Z. K. Tuong, et al., “Rapid Functional Impairment of Natural Killer Cells Following Tumor Entry Limits Anti-Tumor Immunity,” Nature Communications 15 (2024): 683, https://doi.org/10.1038/s41467-024-44789-z.

[30] J. O. J. Davies, K. Stringaris, A. J. Barrett, and K. Rezvani, “Opportunities and Limitations of Natural Killer Cells as Adoptive Therapy for Malignant Disease,” Cytotherapy 16 (2014): 1453–1466, https://doi.org/10.1016/j.jcyt.2014.03.009.

[31] R. Tarazona, B. Sanchez-Correa, I. Casas-Avilés, et al., “Immunosenescence: Limitations of Natural Killer Cell-Based Cancer Immunotherapy,” Cancer Immunology, Immunotherapy 66 (2017): 233–245, https://doi.org/10.1007/s00262-016-1882-x.

[32] D. L. Hermanson, Z. Ni, and D. S. Kaufman, “ Human Pluripotent Stem Cells as a Renewable Source of Natural Killer Cells,” in Hematopoietic Differentiation of Human Pluripotent Stem Cells (Springer, 2015), 69–79.

[33] H. Zhu and D. S. Kaufman, An Improved Method to Produce Clinical-Scale Natural Killer Cells From Human Pluripotent Stem Cells (Springer, 2019).

[34] D. A. Knorr, Z. Ni, D. Hermanson, et al., “Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy,” Stem Cells Translational Medicine 2 (2013): 274–283, https://doi.org/10.5966/sctm.2012-0084.

[35] R. Romee, M. Rosario, M. M. Berrien-Elliott, et al., “Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses Against Myeloid Leukemia,” Science Translational Medicine 8 (2016): 357ra123.

[36] V. Volarevic, B. S. Markovic, M. Gazdic, et al., “Ethical and Safety Issues of Stem Cell-Based Therapy,” International Journal of Medical Sciences 15 (2018): 36–45, https://doi.org/10.7150/ijms.21666.

[37] S. J. Song, Y. Nam, Y. A. Rim, J. H. Ju, and Y. Sohn, “Comparative Analysis of Regulations and Studies on Stem Cell Therapies: Focusing on Induced Pluripotent Stem Cell (iPSC)-Based Treatments,” Stem Cell Research & Therapy 15 (2024): 447, https://doi.org/10.1186/s13287-024-04065-9.

[38] T. Bubela, J. Guebert, and A. Mishra, “Use and Misuse of Material Transfer Agreements: Lessons in Proportionality From Research, Repositories, and Litigation,” PLoS Biology 13 (2015): e1002060, https://doi.org/10.1371/journal.pbio.1002060.

[39] J. Mandal, D. K. Ponnambath, and S. C. Parija, “Ethics of Translational Medical Research,” Tropical Parasitology 7 (2017): 62–64, https://doi.org/10.4103/tp.TP_47_17.

[40] M. Sivonen, K. A. Sirviö, S. Wojciechowski, et al., “Cytokines Impact Natural Killer Cell Phenotype and Functionality Against Glioblastoma In Vitro,” Frontiers in Immunology 14 (2023): 1227064, https://doi.org/10.3389/fimmu.2023.1227064.

[41] J. Han, H. Son, D. Jung, et al., “Comparison of Natural Killer Cells Differentiated From Various Pluripotent Stem Cells,” International Journal of Molecular Sciences 25 (2024): 8209, https://doi.org/10.3390/ijms25158209.

[42] N. A. Maskalenko, D. Zhigarev, and K. S. Campbell, “Harnessing Natural Killer Cells for Cancer Immunotherapy: Dispatching the First Responders,” Nature Reviews. Drug Discovery 21 (2022): 559–577, https://doi.org/10.1038/s41573-022-00413-7.

[43] ISSCR, Recommendation 3.3.2.2: Recommendation 3.3.2.2: Risks for Tumorigenicity Must be Rigorously Assessed for Any Stem Cell-Based Product, Especially If Cells Are Extensively Manipulated in Culture, Genetically Modified, or When Derived From A Pluripotent Source.

[44] A. Biederstadt and K. Rezvani, “Engineering the Next Generation of CAR-NK Immunotherapies,” International Journal of Hematology 114 (2021): 554–571, https://doi.org/10.1007/s12185-021-03209-4.

[45] ISSCR, Recommendation 3.3.2.6: Recommendation 3.3.2.6: Researchers Should Comprehensively Investigate the Type, Extent and Genomic Distribution of Introduced Genetic Alterations as Well as Their Potential Adverse Effects on the Genome and the Biological Properties of the Treated Cells at Short and Long-Term Time Points.

[46] FDA, Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up (Guidance for Industry), 2020, https://www.fda.gov/media/113760/download.

[47] Center for Drug Evaluation, N. M. P. A. Technical Guideline for Research and Evaluation of Cell Therapy Products (Trial), 2017, https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=452c529b299638297210fe4a1294eb31.

[48] 3.4.7.1: The Clinical Use of Genetically Altered (Including Genome-Edited) Somatic Stem Cells Should be Reserved for the Treatment or Correction of Severe Disease and Disability Due To the Inherent Risks, These Products Should Comply With Established Policies And Regulations For Genome Editing And Cell-Based Products.

[49] R. J. Lund, E. Narva, and R. Lahesmaa, “Genetic and Epigenetic Stability of Human Pluripotent Stem Cells,” Nature Reviews. Genetics 13 (2012): 732–744, https://doi.org/10.1038/nrg3271.

[50] F. Fang, S. Xie, M. Chen, et al., “Advances in NK Cell Production,” Cellular & Molecular Immunology 19 (2022): 460–481, https://doi.org/10.1038/s41423-021-00808-3.

[51] ISSCR, 3.2.2.2: The Oversight and Review of Cell Processing and Manufacturing Protocols Should be Rigorous, and Consider The Manipulation of The Cells, Their Source and Intended Use, The Nature Of The Clinical Trial, and The Research Subjects Who Will Be Exposed To Them.

[52] J. Hermsen and M. E. Brown, “Humanized Mouse Models for Evaluation of PSC Immunogenicity,” Current Protocols in Stem Cell Biology 54 (2020): e113, https://doi.org/10.1002/cpsc.113.

[53] D. Fraser, D. M. Weary, E. A. Pajor, and B. N. Milligan, “A Scientific Conception of Animal Welfare That Reflects Ethical Concerns,” Animal Welfare 6 (1997): 187–205.

[54] S. Chen, H. Zhu, and Y. Jounaidi, “Comprehensive Snapshots of Natural Killer Cells Functions, Signaling, Molecular Mechanisms and Clinical Utilization,” Signal Transduction and Targeted Therapy 9 (2024): 302, https://doi.org/10.1038/s41392-024-02005-w.

[55] E. Pernot-Leplay, “China's Approach on Data Privacy Law: A Third Way Between the US and the EU?,” Penn State Journal of Law & International Affairs 8 (2020): 49.

[56] T. Christakis, “Data Free Flow With Trust: Current Landscape, Challenges and Opportunities,” Journal of Cyber Policy 9 (2024): 95–120, https://doi.org/10.1080/23738871.2024.2421838.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.